NovaBay Net Debt from 2010 to 2024

NBY Stock

USD 0.61 0.01 1.61%

NovaBay Pharmaceuticals Net Debt yearly trend continues to be fairly stable with very little volatility. Net Debt will likely drop to about -409.5 K in 2024. Net Debt is the total debt of NovaBay Pharmaceuticals minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. View All Fundamentals

Net Debt

First Reported

2005-12-31

Previous Quarter

1.3 M

Current Value

486 K

Quarterly Volatility

4.1 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check NovaBay Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NovaBay Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 229.5 K, Interest Expense of 4.6 M or Other Operating Expenses of 16.9 M, as well as many indicators such as Price To Sales Ratio of 0.0555, Dividend Yield of 0.0 or PTB Ratio of 0.25. NovaBay financial statements analysis is a perfect complement when working with NovaBay Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of NovaBay Pharmaceuticals Correlation against competitors.

For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

Latest NovaBay Pharmaceuticals' Net Debt Growth Pattern

Below is the plot of the Net Debt of NovaBay Pharmaceuticals over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. NovaBay Pharmaceuticals' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NovaBay Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

Net Debt

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Net Debt

Timeline

NovaBay Net Debt Regression Statistics

	Arithmetic Mean	(5,422,500)
	Coefficient Of Variation	(77.50)
	Mean Deviation	3,606,467
	Median	(3,321,000)
	Standard Deviation	4,202,591
	Sample Variance	17.7T
	Range	12.3M
	R-Value	0.40
	Mean Square Error	15.9T
	R-Squared	0.16
	Significance	0.14
	Slope	378,652
	Total Sum of Squares	247.3T

NovaBay Net Debt History

	2024	-409.5 K
	2023	-390 K
	2022	-3.3 M
	2021	-7 M
	2020	-11.4 M
	2019	-2.9 M
	2018	-3.2 M

Other Fundumenentals of NovaBay Pharmaceuticals

Net Debt To E B I T D A

NovaBay Pharmaceuticals Net Debt component correlations

	Total Assets	Total Stockholder Equity	Total Liab	Net Debt	Retained Earnings	Accounts Payable	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Term Debt	Net Receivables	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.83	0.45	-0.61	-0.25	-0.16	0.87	0.59	0.3	-0.11	0.0	-0.28	0.17	0.24	-0.17	-0.4	0.09	0.45	0.47	0.25
Total Stockholder Equity	0.83		-0.11	-0.76	-0.04	-0.4	0.88	0.62	0.33	0.06	-0.18	-0.12	0.58	0.1	-0.34	-0.42	0.19	0.5	0.51	0.23
Total Liab	0.45	-0.11		0.06	-0.34	0.37	0.16	0.1	-0.06	-0.29	0.24	-0.29	-0.6	0.25	0.24	-0.02	-0.14	0.04	0.06	0.04
Net Debt	-0.61	-0.76	0.06		-0.39	0.22	-0.86	-0.49	0.19	0.16	0.17	0.21	-0.69	0.3	0.22	0.15	-0.55	-0.29	-0.4	0.35
Retained Earnings	-0.25	-0.04	-0.34	-0.39		-0.06	0.06	-0.08	-0.42	0.05	-0.13	0.05	0.51	-0.94	-0.08	0.31	0.44	-0.42	-0.27	-0.65
Accounts Payable	-0.16	-0.4	0.37	0.22	-0.06		-0.29	0.14	0.09	-0.65	0.23	-0.48	-0.69	0.0	0.05	-0.16	0.12	-0.17	-0.13	0.11
Total Current Assets	0.87	0.88	0.16	-0.86	0.06	-0.29		0.51	0.15	-0.1	-0.02	-0.28	0.51	-0.04	-0.17	-0.17	0.27	0.28	0.32	-0.04
Common Stock	0.59	0.62	0.1	-0.49	-0.08	0.14	0.51		0.19	-0.28	0.05	-0.28	0.06	0.16	-0.61	-0.39	0.12	0.53	0.54	0.37
Property Plant Equipment	0.3	0.33	-0.06	0.19	-0.42	0.09	0.15	0.19		-0.08	0.26	-0.36	-0.19	0.35	-0.08	-0.42	-0.14	-0.02	-0.1	0.79
Current Deferred Revenue	-0.11	0.06	-0.29	0.16	0.05	-0.65	-0.1	-0.28	-0.08		-0.69	0.88	0.28	0.01	0.13	0.39	-0.56	-0.06	-0.06	0.05
Short Term Debt	0.0	-0.18	0.24	0.17	-0.13	0.23	-0.02	0.05	0.26	-0.69		-0.74	-0.28	0.01	-0.17	-0.04	0.19	-0.27	-0.35	0.08
Net Receivables	-0.28	-0.12	-0.29	0.21	0.05	-0.48	-0.28	-0.28	-0.36	0.88	-0.74		0.15	0.06	0.08	0.38	-0.53	0.06	0.05	-0.06
Net Tangible Assets	0.17	0.58	-0.6	-0.69	0.51	-0.69	0.51	0.06	-0.19	0.28	-0.28	0.15		-0.41	-0.13	0.01	0.4	0.14	0.2	-0.39
Capital Surpluse	0.24	0.1	0.25	0.3	-0.94	0.0	-0.04	0.16	0.35	0.01	0.01	0.06	-0.41		0.02	-0.35	-0.43	0.52	0.39	0.67
Deferred Long Term Liab	-0.17	-0.34	0.24	0.22	-0.08	0.05	-0.17	-0.61	-0.08	0.13	-0.17	0.08	-0.13	0.02		0.18	0.12	-0.14	-0.13	-0.07
Short Long Term Debt	-0.4	-0.42	-0.02	0.15	0.31	-0.16	-0.17	-0.39	-0.42	0.39	-0.04	0.38	0.01	-0.35	0.18		-0.39	-0.66	-0.67	-0.43
Cash And Equivalents	0.09	0.19	-0.14	-0.55	0.44	0.12	0.27	0.12	-0.14	-0.56	0.19	-0.53	0.4	-0.43	0.12	-0.39		0.11	0.22	-0.34
Net Invested Capital	0.45	0.5	0.04	-0.29	-0.42	-0.17	0.28	0.53	-0.02	-0.06	-0.27	0.06	0.14	0.52	-0.14	-0.66	0.11		0.98	0.3
Net Working Capital	0.47	0.51	0.06	-0.4	-0.27	-0.13	0.32	0.54	-0.1	-0.06	-0.35	0.05	0.2	0.39	-0.13	-0.67	0.22	0.98		0.19
Capital Stock	0.25	0.23	0.04	0.35	-0.65	0.11	-0.04	0.37	0.79	0.05	0.08	-0.06	-0.39	0.67	-0.07	-0.43	-0.34	0.3	0.19

Click cells to compare fundamentals

About NovaBay Pharmaceuticals Financial Statements

NovaBay Pharmaceuticals investors use historical fundamental indicators, such as NovaBay Pharmaceuticals' Net Debt, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in NovaBay Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Net Debt	-390 K	-409.5 K
Net Debt To EBITDA	0.08	0.08

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NovaBay Net Debt from 2010 to 2024

Latest NovaBay Pharmaceuticals' Net Debt Growth Pattern

NovaBay Net Debt Regression Statistics

NovaBay Net Debt History

Other Fundumenentals of NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Net Debt component correlations

About NovaBay Pharmaceuticals Financial Statements

Also Currently Popular

Additional Tools for NovaBay Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY